

Practical Perspectives: Experts Review Actual Cases of Patients with Advanced Gastroesophageal Cancers

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. In a Phase II study of first-line zanidatamab and chemotherapy for HER2-positive advanced gastroesophageal adenocarcinomas, what was the approximate objective response rate?
 - a. 30%
 - b. 45%
 - c. 62%
 - d. 84%**
 - e. 100%

2. The Phase III DESTINY-Gastric04 study evaluating trastuzumab deruxtecan versus ramucirumab/paclitaxel for previously treated HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma reported what finding at the interim analysis?
 - a. Inferior overall survival (OS) outcomes with trastuzumab deruxtecan (T-DXd)
 - b. A nonsignificant trend toward OS improvement with T-DXd
 - c. A statistically significant improvement in OS with T-DXd**
 - d. No efficacy findings have been reported yet

3. Which of the following drug types best describes the mechanism of action of zanidatamab?
 - a. Anti-PD-1/PD-L1 antibody
 - b. Biparatopic bispecific HER2-targeting antibody**
 - c. CLDN18.2-targeting monoclonal antibody
 - d. TROP2-directed antibody-drug conjugate (ADC)

4. Which of the following descriptions best reflects the design of the HERIZON-GEA-01 study of zanidatamab for metastatic HER2-positive gastroesophageal adenocarcinoma?
 - a. A Phase I dose-escalation trial of zanidatamab and chemotherapy as first-line treatment
 - b. A Phase II dose-optimization trial of 2 different doses of zanidatamab monotherapy for relapsed/refractory disease
 - c. A Phase III trial comparing zanidatamab and chemotherapy with or without tislelizumab to trastuzumab and chemotherapy as first-line treatment**

5. What is the mechanism of action of the investigational agent AZD0901?
 - a. Biparatopic HER2-targeting bispecific antibody
 - b. CLDN18.2-targeting ADC**
 - c. HER2-targeting ADC
 - d. TROP2-targeting ADC
 - e. B7-H3 targeting ADC